25 May 2018

David Woldbye receives funding for company Combigene

The gene therapy company CombiGene that was founded by Associate Prof David Woldbye (Institute of Neuroscience, UCPH) together with Prof Merab Kokaia (Lund University), has just received important funding of 25 MIO DKK from Horizon 2020, EU framework programme. This will now allow the company to conduct toxicology studies and to produce gene therapy vectors of GMP quality necessary for future human clinical testing. GMP production is costly and this funding from the EU is a big step forward in paving the way for gene therapy trials against epilepsy in humans for the first time.